Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
MSH2 gene Associated Syndrome Name: Lynch syndrome/Hereditary NonPolyposis Colorectal Cancer (HNPCC) MSH2 Summary Cancer Risk Table CANCER Colorectal GENETIC CANCER RISK High Risk Endometrial High Risk Gastric High Risk Ovarian High Risk Pancreatic Elevated Risk Other High Risk MSH2 gene Overview Lynch syndrome 1, 2, 3, 4, 5, 6, 7, 8 Individuals with mutations in MSH2 have a condition called Lynch syndrome. This condition is also known as Hereditary Non-Polyposis Colon Cancer (HNPCC). Men and women with Lynch syndrome due to mutations in MSH2 have a high risk of developing colorectal cancer, often at young ages. Colorectal cancer in patients with Lynch syndrome develops from adenomatous polyps which progress to cancer more quickly than polyps in individuals who do not have Lynch syndrome. Women with Lynch syndrome due to mutations in MSH2 have a high risk for developing endometrial and ovarian cancer, often at young ages. Patients with Lynch syndrome due to mutations in MSH2 also have an increased risk of developing a wide variety of other cancers, including gastric, small bowel, urinary tract, hepatobiliary tract, brain (usually glioblastoma), sebaceous gland, and pancreatic. Studies have investigated the possibility that patients with Lynch syndrome have an increased risk for other cancers, including breast cancer, prostate cancer, and adrenocortical carcinoma. However, the data are not conclusive at this time and there are currently no medical management guidelines related to these cancers. Patients with Lynch syndrome have a high risk for developing second primary cancers following an initial diagnosis of colorectal or endometrial cancer. This includes a high risk for endometrial cancer in women following colorectal cancer and vice versa, a high risk for a second primary colorectal cancer in any portions of the colon or rectum remaining after surgical treatment, and a high risk for other Lynch associated cancers, such as those of the upper gastrointestinal tract, urinary tract, and other sites. Although there are high risks for cancer in patients with Lynch syndrome, many of these risks can be greatly reduced with appropriate medical management. Guidelines for the medical management of patients with Lynch syndrome have been developed by the National Comprehensive Cancer Network 1 (NCCN) and other expert groups. These are listed below. It is recommended that patients with an MSH2 mutation and a diagnosis of Lynch syndrome be managed by a multidisciplinary team with expertise in medical genetics and the care of patients with this condition. MSH2 gene Cancer Risk Table CANCER TYPE AGE RANGE 1, 6 Colorectal To age 70 Endometrial To age 70 Overall cancer risk (Lynch cancers) Risk for a second Lynchrelated cancer after a first 10, 11 cancer diagnosis Ovarian To age 70 Gastric To age 70 Small Bowel To age 70 Urinary Tract To age 70 Pancreatic To age 70 Hepatobiliary Tract To age 70 Central Nervous System To age 70 Sebaceous Neoplasms To age 70 1, 6 1, 6 1, 6 1, 6 1, 6, 8 1, 2, 6 1, 6 1, 6 1, 6 CANCER RISK RISK FOR GENERAL 9 POPULATION 52%-82% 1.9% 25%-60% 1.6% Increased risk NA 4%-12% 0.7% 6%-13% 0.3% 3%-6% 0.1% 1%-7%, or higher <1.0% 1%-6% 0.5% 1.4%-4% 0.4% 1%-3% 0.4% 1%-9% <1.0% MSH2 Cancer Risk Management Table The overview of medical management options provided is a summary of professional society guidelines as of the last Myriad update shown on this page. The specific reference provided (e.g., NCCN guidelines) should be consulted for more details and up-to-date information before developing a treatment plan for a particular patient. This overview is provided for informational purposes only and does not constitute a recommendation. While the medical society guidelines summarized herein provide important and useful information, medical management decisions for any particular patient should be made in consultation between that patient and his or her healthcare provider and may differ from society guidelines based on a complete understanding of the patient's personal medical history, surgeries and other treatments. CANCER TYPE Colorectal 2 PROCEDURE 6, 7 Colonoscopy AGE TO BEGIN 20 to 25 years, or 2 to 5 years younger than the earliest diagnosis in family if it is under age 25 FREQUENCY Every 1 to 2 years CANCER TYPE PROCEDURE AGE TO BEGIN Colorectal surgical evaluation may be appropriate for 6 some patients Individualized NA Individualized Individualized Patient education about endometrial cancer symptoms. Individualized NA Consider pelvic examination, endometrial sampling and 6, 7 transvaginal ultrasound. 30 to 35 years Annually After completion of childbearing NA Consider bilateral salpingo-oophorectomy. Age 40 or after completion of childbearing NA Consider transvaginal ultrasound and CA-125 6, 7 measurement. 30 to 35 years NA Treat for Helicobacter pylori infection if present. Individualized NA Consider upper endoscopy, particularly for patients with additional risk factors for gastric cancer, such as family history or Asian ancestry. Consider biopsy of the 6, 7, 12 antrum. 30 to 35 years Every 2 to 5 years Small Bowel Consider upper endoscopy, particularly for patients with additional risk factors for small bowel cancer, such 6, 7 as family history. 30 to 35 years Every 3 to 5 years Urinary Tract Consider urinalysis. 30 to 35 years Annually Pancreatic Consider available options for pancreatic cancer screening, including the possibility of endoscopic ultrasonography (EUS) and MRI/magnetic resonance cholangiopancreatography (MRCP). It is recommended that patients who are candidates for pancreatic cancer screening be managed by a multidisciplinary team with experience in the screening for pancreatic cancer, 13 preferably within research protocols. Individualized NA Hepatobiliary Tract Currently there are no specific medical management guidelines for hepatobiliary cancer risk in mutation 6 carriers. NA NA Central Nervous System Physical/neurological examination 25 to 30 years Annually 6, 7 Consider the use of aspirin as a risk-reduction agent Endometrial 6 6, 7 Consider hysterectomy. Ovarian Gastric 3 FREQUENCY 6, 7 7 6, 7 6 CANCER TYPE Sebaceous Neoplasms PROCEDURE Currently there are no specific medical management guidelines for sebaceous neoplasm risk in mutation carriers. AGE TO BEGIN NA FREQUENCY NA Information for Family Members The following information for Family Members will appear as part of the MMT for a patient found to have a mutation in the MSH2 gene. A major potential benefit of myRisk genetic testing for hereditary cancer risk is the opportunity to prevent cancer in relatives of patients in whom clinically significant mutations are identified. Healthcare providers have an important role in making sure that patients with clinically significant mutations are informed about the risks to relatives, and ways in which genetic testing can guide lifesaving interventions. In rare instances, an individual may inherit mutations in both copies of the MSH2 gene, leading to the condition Constitutional Mismatch Repair-Deficiency syndrome (CMMR-D). Individuals with CMMR-D often have significant complications in childhood, including colorectal polyposis and a high risk for colorectal, small bowel, brain, and hematologic cancers. Individuals with CMMR-D often have café-au-lait spots. The children of this patient are at risk of inheriting CMMR-D only if the other parent is also a carrier of a MSH2 mutation. Screening the spouse/partner of this 1 patient for MSH2 mutations may be appropriate. References 1. Kohlmann W, Gruber SB. Lynch Syndrome. 2014 May 22. In:Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from http://www.ncbi.nlm.nih.gov/books/NBK1211/ PMID: 20301390. 2. Kastrinos F, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009 302:1790-5. PMID: 19861671. 3. Lin KM, et al. Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population. Dis Colon Rectum. 1998 41:428-33. PMID: 9559626. 4. Win AK, et al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst. 2013 105:274-9. PMID: 23385444. 5. Win AK, et al. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst. 2012 104:1363-72. PMID: 22933731. 6. Provenzale D, et al. NCCN Clinical Practice Guidelines in Oncology® Genetic/Familial High-Risk Assessment: Colorectal. V 2.2016. September 26. Available at http://www.nccn.org. 7. Giardiello FM, et al. Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2014 109:1159-79. PMID: 25070057. 8. Joost P, et al. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations. Urology. 2015 86:1212-7. PMID: 26385421. 4 9. Surveillance Research Program, National Cancer Institute SEER*Stat software (seer.cancer.gov/seerstat) V 8.0.1, Nov 19, 2012. 10. Larsen Haidle J, Howe JR. Juvenile Polyposis Syndrome. 2015 Dec 3. In: Pagon RA, et al., editors. GeneReviews® [Internet]. Available from http://www.ncbi.nlm.nih.gov/books/NBK1469/ PMID: 20301642. 11. Provenzale D, et al. NCCN Clinical Practice Guidelines in Oncology® Colorectal Cancer Screening. V 2.2016. October 20. Available at http://www.nccn.org. 12. Ajani JA, et al. NCCN Clinical Practice Guidelines in Oncology®: Gastric Cancer. V 3.2016. August 3. Available at http://www.nccn.org. 13. Canto MI, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013 62:339-47. PMID: 23135763. Last Updated on 10-Jan-2017 5